Ventyx Biosciences announced new long-term extension (LTE) data from its Phase 2 trial of tamuzimod (VTX002) in ulcerative colitis. These 52-week results were presented on October 15, 2024, during the United European Gastroenterology (UEG) Week meeting in Vienna, Austria. The data continues to reinforce the potential best-in-class profile of tamuzimod.
The trial demonstrated high rates of clinical remission and endoscopic remission among LTE completers at Week 52. Tamuzimod also showed a potential best-in-class safety profile among all oral options for ulcerative colitis therapy. This comprehensive data set supports the drug's therapeutic potential.
Raju Mohan, PhD, Chief Executive Officer, stated that these results position tamuzimod as a potential backbone for future combination therapies for ulcerative colitis. The positive long-term data is expected to inform the company's strategy for advancing this S1P1R modulator.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.